📣 VC round data is live. Check it out!
- Public Comps
- Lexeo Therapeutics
Lexeo Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lexeo Therapeutics and similar public comparables like Eupraxia Pharmaceuticals, Atea Pharmaceuticals, Vanda Pharmaceuticals, PureTech Health and more.
Lexeo Therapeutics Overview
About Lexeo Therapeutics
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Founded
2017
HQ

Employees
72
Website
Financials (LTM)
EV
$282M
Valuation Multiples
Start free trialLexeo Therapeutics Financials
Lexeo Therapeutics reported last 12-month revenue of — and negative EBITDA of ($112M).
In the same LTM period, Lexeo Therapeutics generated ($45K) in gross profit, ($112M) in EBITDA losses, and had net loss of ($103M).
Revenue (LTM)
Lexeo Therapeutics P&L
In the most recent fiscal year, Lexeo Therapeutics reported revenue of — and EBITDA of ($98M).
Lexeo Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.
Financial data powered by Morningstar, Inc.
Lexeo Therapeutics Stock Performance
Lexeo Therapeutics has current market cap of $455M, and enterprise value of $282M.
Market Cap Evolution
Lexeo Therapeutics' stock price is $5.80.
Lexeo Therapeutics share price increased by 1.9% in the last 30 days, and by 246.8% in the last year.
Lexeo Therapeutics has an EPS (earnings per share) of $-1.27.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $282M | $455M | 6.5% | 1.9% | -19.2% | 246.8% | $-1.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLexeo Therapeutics Valuation Multiples
Lexeo Therapeutics trades at (2.5x) EV/EBITDA.
EV / Revenue (LTM)
Lexeo Therapeutics Financial Valuation Multiples
As of May 5, 2026, Lexeo Therapeutics has market cap of $455M and EV of $282M.
Lexeo Therapeutics has a P/E ratio of (4.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lexeo Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Lexeo Therapeutics Margins & Growth Rates
Lexeo Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Lexeo Therapeutics Operational KPIs
Lexeo Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Lexeo Therapeutics Competitors
Lexeo Therapeutics competitors include Eupraxia Pharmaceuticals, Atea Pharmaceuticals, Vanda Pharmaceuticals, PureTech Health, Achieve Life Sciences, Avacta Group, Climb Bio, YungShin Global Holding, Neurogene and Swedencare.
Most Lexeo Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| — | — | (10.6x) | (12.7x) | |||
| — | — | (0.9x) | (0.9x) | |||
| 0.9x | 0.9x | (1.5x) | — | |||
| 43.2x | 43.2x | (3.3x) | (1.4x) | |||
| — | — | (8.0x) | — | |||
| 3076.2x | 166.9x | (19.7x) | (14.4x) | |||
| — | — | (5.3x) | (5.0x) | |||
| 1.6x | — | 8.3x | — | |||
This data is available for Pro users. Sign up to see all Lexeo Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Lexeo Therapeutics Funding History
Before going public, Lexeo Therapeutics raised $185M in total equity funding, across 2 rounds.
Lexeo Therapeutics Funding Rounds
Lexeo Therapeutics M&A Activity
Lexeo Therapeutics has acquired 1 company to date.
Last acquisition by Lexeo Therapeutics was on July 21st 2021. Lexeo Therapeutics acquired Stelios Therapeutics for undisclosed valuation.
Latest Acquisitions by Lexeo Therapeutics
| Description | Stelios Therapeutics is a San Diego-based gene therapy developer creating AAV vectors for rare inherited cardiac diseases. Originating from University of California San Diego research, the company targets conditions like hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. With expertise in cardiac-specific promoters and capsid engineering, Stelios advances preclinical programs toward IND-enabling studies for systemic delivery of corrective genes. |
| HQ Country | |
| HQ City | San Diego, CA |
| Deal Date | 21 Jul 2021 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Lexeo Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lexeo Therapeutics
| When was Lexeo Therapeutics founded? | Lexeo Therapeutics was founded in 2017. |
| Where is Lexeo Therapeutics headquartered? | Lexeo Therapeutics is headquartered in United States. |
| How many employees does Lexeo Therapeutics have? | As of today, Lexeo Therapeutics has over 72 employees. |
| Who is the CEO of Lexeo Therapeutics? | Lexeo Therapeutics' CEO is Richard Nolan Townsend. |
| Is Lexeo Therapeutics publicly listed? | Yes, Lexeo Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Lexeo Therapeutics? | Lexeo Therapeutics trades under LXEO ticker. |
| When did Lexeo Therapeutics go public? | Lexeo Therapeutics went public in 2023. |
| Who are competitors of Lexeo Therapeutics? | Lexeo Therapeutics main competitors include Eupraxia Pharmaceuticals, Atea Pharmaceuticals, Vanda Pharmaceuticals, PureTech Health, Achieve Life Sciences, Avacta Group, Climb Bio, YungShin Global Holding, Neurogene, Swedencare. |
| What is the current market cap of Lexeo Therapeutics? | Lexeo Therapeutics' current market cap is $455M. |
| Is Lexeo Therapeutics profitable? | No, Lexeo Therapeutics is not profitable. |
| What is the current EBITDA of Lexeo Therapeutics? | Lexeo Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Lexeo Therapeutics? | Current EBITDA multiple of Lexeo Therapeutics is (2.5x). |
| What is the current FCF of Lexeo Therapeutics? | Lexeo Therapeutics' last 12 months FCF is ($103M). |
| What is the current EV/FCF multiple of Lexeo Therapeutics? | Current FCF multiple of Lexeo Therapeutics is (2.7x). |
| How many companies Lexeo Therapeutics has acquired to date? | As of May 2026, Lexeo Therapeutics has acquired 1 company. |
| What was the largest acquisition by Lexeo Therapeutics? | None of the M&A deals Lexeo Therapeutics has completed have disclosed valuations. |
| What companies Lexeo Therapeutics acquired? | Lexeo Therapeutics acquired Stelios Therapeutics. |
| In how many companies Lexeo Therapeutics has invested to date? | Lexeo Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Lexeo Therapeutics
Lists including Lexeo Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
